JP2008521870A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2008521870A5 JP2008521870A5 JP2007543910A JP2007543910A JP2008521870A5 JP 2008521870 A5 JP2008521870 A5 JP 2008521870A5 JP 2007543910 A JP2007543910 A JP 2007543910A JP 2007543910 A JP2007543910 A JP 2007543910A JP 2008521870 A5 JP2008521870 A5 JP 2008521870A5
- Authority
- JP
- Japan
- Prior art keywords
- seq
- dom4
- sequence
- dom7r
- dom7h
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
- 102000010932 Interleukin-1 receptor type 1 Human genes 0.000 claims 31
- 108050001109 Interleukin-1 receptor type 1 Proteins 0.000 claims 31
- 101100268517 Mus musculus Serpina1d gene Proteins 0.000 claims 30
- 108060003951 Immunoglobulin Proteins 0.000 claims 23
- 102000018358 immunoglobulin Human genes 0.000 claims 23
- 239000005557 antagonist Substances 0.000 claims 20
- 125000003275 alpha amino acid group Chemical group 0.000 claims 17
- 229920001184 polypeptide Polymers 0.000 claims 13
- 102000004196 processed proteins & peptides Human genes 0.000 claims 13
- 108090000765 processed proteins & peptides Proteins 0.000 claims 13
- 239000003814 drug Substances 0.000 claims 12
- 208000023504 respiratory system disease Diseases 0.000 claims 12
- 102000000589 Interleukin-1 Human genes 0.000 claims 11
- 108010002352 Interleukin-1 Proteins 0.000 claims 11
- 102000008394 Immunoglobulin Fragments Human genes 0.000 claims 10
- 108010021625 Immunoglobulin Fragments Proteins 0.000 claims 10
- 101001076407 Homo sapiens Interleukin-1 receptor antagonist protein Proteins 0.000 claims 9
- 208000014085 Chronic respiratory disease Diseases 0.000 claims 8
- 102100033732 Tumor necrosis factor receptor superfamily member 1A Human genes 0.000 claims 8
- 229940119178 Interleukin 1 receptor antagonist Drugs 0.000 claims 7
- 102000051628 Interleukin-1 receptor antagonist Human genes 0.000 claims 7
- 210000004602 germ cell Anatomy 0.000 claims 7
- 239000003407 interleukin 1 receptor blocking agent Substances 0.000 claims 7
- 108090000623 proteins and genes Proteins 0.000 claims 7
- FWMNVWWHGCHHJJ-SKKKGAJSSA-N 4-amino-1-[(2r)-6-amino-2-[[(2r)-2-[[(2r)-2-[[(2r)-2-amino-3-phenylpropanoyl]amino]-3-phenylpropanoyl]amino]-4-methylpentanoyl]amino]hexanoyl]piperidine-4-carboxylic acid Chemical compound C([C@H](C(=O)N[C@H](CC(C)C)C(=O)N[C@H](CCCCN)C(=O)N1CCC(N)(CC1)C(O)=O)NC(=O)[C@H](N)CC=1C=CC=CC=1)C1=CC=CC=C1 FWMNVWWHGCHHJJ-SKKKGAJSSA-N 0.000 claims 6
- 101710187743 Tumor necrosis factor receptor superfamily member 1A Proteins 0.000 claims 6
- 238000012377 drug delivery Methods 0.000 claims 6
- 101001076418 Homo sapiens Interleukin-1 receptor type 1 Proteins 0.000 claims 5
- 208000006545 Chronic Obstructive Pulmonary Disease Diseases 0.000 claims 4
- 102000008100 Human Serum Albumin Human genes 0.000 claims 4
- 108091006905 Human Serum Albumin Proteins 0.000 claims 4
- 102000007562 Serum Albumin Human genes 0.000 claims 4
- 108010071390 Serum Albumin Proteins 0.000 claims 4
- 239000012634 fragment Substances 0.000 claims 4
- 238000004519 manufacturing process Methods 0.000 claims 4
- 150000001413 amino acids Chemical class 0.000 claims 3
- 210000004027 cell Anatomy 0.000 claims 3
- 125000003827 glycol group Chemical group 0.000 claims 3
- 238000001727 in vivo Methods 0.000 claims 3
- 238000007910 systemic administration Methods 0.000 claims 3
- 102000006395 Globulins Human genes 0.000 claims 2
- 108010044091 Globulins Proteins 0.000 claims 2
- 102100026120 IgG receptor FcRn large subunit p51 Human genes 0.000 claims 2
- 102000019223 Interleukin-1 receptor Human genes 0.000 claims 2
- 108050006617 Interleukin-1 receptor Proteins 0.000 claims 2
- 239000002202 Polyethylene glycol Substances 0.000 claims 2
- 206010036790 Productive cough Diseases 0.000 claims 2
- 102000004338 Transferrin Human genes 0.000 claims 2
- 108090000901 Transferrin Proteins 0.000 claims 2
- 102000007238 Transferrin Receptors Human genes 0.000 claims 2
- 108010033576 Transferrin Receptors Proteins 0.000 claims 2
- 108060008682 Tumor Necrosis Factor Proteins 0.000 claims 2
- 102000000852 Tumor Necrosis Factor-alpha Human genes 0.000 claims 2
- 239000000427 antigen Substances 0.000 claims 2
- 102000036639 antigens Human genes 0.000 claims 2
- 108091007433 antigens Proteins 0.000 claims 2
- 238000001574 biopsy Methods 0.000 claims 2
- 210000004969 inflammatory cell Anatomy 0.000 claims 2
- 230000002401 inhibitory effect Effects 0.000 claims 2
- 210000004072 lung Anatomy 0.000 claims 2
- 108010068617 neonatal Fc receptor Proteins 0.000 claims 2
- 239000008194 pharmaceutical composition Substances 0.000 claims 2
- 229920001223 polyethylene glycol Polymers 0.000 claims 2
- 210000004879 pulmonary tissue Anatomy 0.000 claims 2
- 210000003802 sputum Anatomy 0.000 claims 2
- 208000024794 sputum Diseases 0.000 claims 2
- 238000007920 subcutaneous administration Methods 0.000 claims 2
- 238000002198 surface plasmon resonance spectroscopy Methods 0.000 claims 2
- 230000037317 transdermal delivery Effects 0.000 claims 2
- 239000012581 transferrin Substances 0.000 claims 2
- NFGXHKASABOEEW-UHFFFAOYSA-N 1-methylethyl 11-methoxy-3,7,11-trimethyl-2,4-dodecadienoate Chemical compound COC(C)(C)CCCC(C)CC=CC(C)=CC(=O)OC(C)C NFGXHKASABOEEW-UHFFFAOYSA-N 0.000 claims 1
- 102000004889 Interleukin-6 Human genes 0.000 claims 1
- 108090001005 Interleukin-6 Proteins 0.000 claims 1
- 102000004890 Interleukin-8 Human genes 0.000 claims 1
- 108090001007 Interleukin-8 Proteins 0.000 claims 1
- 239000002775 capsule Substances 0.000 claims 1
- 229940112141 dry powder inhaler Drugs 0.000 claims 1
- 210000003979 eosinophil Anatomy 0.000 claims 1
- 108020001507 fusion proteins Proteins 0.000 claims 1
- 102000037865 fusion proteins Human genes 0.000 claims 1
- 102000046824 human IL1RN Human genes 0.000 claims 1
- 238000000099 in vitro assay Methods 0.000 claims 1
- 229940100601 interleukin-6 Drugs 0.000 claims 1
- 229940096397 interleukin-8 Drugs 0.000 claims 1
- XKTZWUACRZHVAN-VADRZIEHSA-N interleukin-8 Chemical compound C([C@H](NC(=O)[C@H](CC(O)=O)NC(=O)[C@H](CC=1C2=CC=CC=C2NC=1)NC(=O)[C@@H](NC(C)=O)CCSC)C(=O)N[C@@H](CC(O)=O)C(=O)N[C@@H](CC(O)=O)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CC(N)=O)C(=O)N[C@@H](CC=1C=CC=CC=1)C(=O)N[C@@H]([C@@H](C)O)C(=O)NCC(=O)N[C@@H](CCSC)C(=O)N1[C@H](CCC1)C(=O)N1[C@H](CCC1)C(=O)N[C@@H](C)C(=O)N[C@H](CC(O)=O)C(=O)N[C@H](CCC(O)=O)C(=O)N[C@H](CC(O)=O)C(=O)N[C@H](CC=1C=CC(O)=CC=1)C(=O)N[C@H](CO)C(=O)N1[C@H](CCC1)C(N)=O)C1=CC=CC=C1 XKTZWUACRZHVAN-VADRZIEHSA-N 0.000 claims 1
- 238000001361 intraarterial administration Methods 0.000 claims 1
- 238000007918 intramuscular administration Methods 0.000 claims 1
- 238000007912 intraperitoneal administration Methods 0.000 claims 1
- 238000007913 intrathecal administration Methods 0.000 claims 1
- 238000001990 intravenous administration Methods 0.000 claims 1
- 210000004698 lymphocyte Anatomy 0.000 claims 1
- 210000002540 macrophage Anatomy 0.000 claims 1
- 229940071648 metered dose inhaler Drugs 0.000 claims 1
- 239000006199 nebulizer Substances 0.000 claims 1
- 230000036961 partial effect Effects 0.000 claims 1
- 229920001515 polyalkylene glycol Polymers 0.000 claims 1
- 238000002203 pretreatment Methods 0.000 claims 1
- 230000002685 pulmonary effect Effects 0.000 claims 1
- 230000002829 reductive effect Effects 0.000 claims 1
- 210000002966 serum Anatomy 0.000 claims 1
- 239000003826 tablet Substances 0.000 claims 1
- 238000013389 whole blood assay Methods 0.000 claims 1
Applications Claiming Priority (4)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US63236104P | 2004-12-02 | 2004-12-02 | |
| PCT/GB2005/002163 WO2005118642A2 (en) | 2004-06-01 | 2005-05-31 | Bispecific fusion antibodies with enhanced serum half-life |
| GBGB0521621.3A GB0521621D0 (en) | 2005-10-24 | 2005-10-24 | Tumor necrosis factor receptor 1 antagonists for treating respiratory diseases |
| PCT/GB2005/004601 WO2006059108A2 (en) | 2004-12-02 | 2005-12-01 | ANTI-IL-IRl SINGLE DOMAIN ANTIBODIES AND THERAPEUTIC USES |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| JP2008521870A JP2008521870A (ja) | 2008-06-26 |
| JP2008521870A5 true JP2008521870A5 (enExample) | 2009-01-22 |
Family
ID=38792215
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2007543910A Pending JP2008521870A (ja) | 2004-12-02 | 2005-12-01 | 抗ｉｌ−１ｒ１単一ドメイン抗体および治療使用 |
Country Status (13)
| Country | Link |
|---|---|
| US (1) | US20090191217A1 (enExample) |
| EP (1) | EP1863847A2 (enExample) |
| JP (1) | JP2008521870A (enExample) |
| KR (1) | KR20070086896A (enExample) |
| CN (1) | CN101133084A (enExample) |
| AU (2) | AU2005311101B8 (enExample) |
| BR (1) | BRPI0518622A2 (enExample) |
| CA (1) | CA2588892A1 (enExample) |
| IL (1) | IL183458A0 (enExample) |
| MA (1) | MA29669B1 (enExample) |
| MX (1) | MX2007006593A (enExample) |
| NO (1) | NO20073337L (enExample) |
| WO (1) | WO2006059108A2 (enExample) |
Families Citing this family (70)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US9028822B2 (en) | 2002-06-28 | 2015-05-12 | Domantis Limited | Antagonists against TNFR1 and methods of use therefor |
| US9321832B2 (en) * | 2002-06-28 | 2016-04-26 | Domantis Limited | Ligand |
| EP1558647B1 (en) * | 2002-11-08 | 2015-06-10 | Ablynx N.V. | Single domain antibodies directed against tumour necrosis factor-alpha and uses therefor |
| US20060034845A1 (en) | 2002-11-08 | 2006-02-16 | Karen Silence | Single domain antibodies directed against tumor necrosis factor alpha and uses therefor |
| US9320792B2 (en) | 2002-11-08 | 2016-04-26 | Ablynx N.V. | Pulmonary administration of immunoglobulin single variable domains and constructs thereof |
| EP3299393A1 (en) | 2002-11-08 | 2018-03-28 | Ablynx N.V. | Single domain antibodies directed against tumour necrosis factor-alpha and uses therefor |
| WO2010081856A1 (en) * | 2009-01-14 | 2010-07-22 | Ablynx Nv | Pulmonary administration of immunoglobulin single variable domains and constructs thereof |
| GB0521621D0 (en) * | 2005-10-24 | 2005-11-30 | Domantis Ltd | Tumor necrosis factor receptor 1 antagonists for treating respiratory diseases |
| EP1957537A2 (en) * | 2005-12-01 | 2008-08-20 | Domantis Limited | Competitive domain antibody formats that bind interleukin 1 receptor type 1 |
| KR20080077238A (ko) * | 2005-12-01 | 2008-08-21 | 도만티스 리미티드 | 인터루킨 1 수용체 타입 1에 결합하는 비경쟁적 도메인항체 포맷 |
| CA2660519A1 (en) * | 2006-08-10 | 2008-02-21 | Roy C. Levitt | Localized therapy of lower airways inflammatory disorders with proinflammatory cytokine inhibitors |
| AU2013270447B2 (en) * | 2006-08-10 | 2016-10-13 | Onspira Therapeutics, Inc. | Localized therapy of lower airways inflammatory disorders with proinflammatory cytokine inhibitors |
| GB0621513D0 (en) | 2006-10-30 | 2006-12-06 | Domantis Ltd | Novel polypeptides and uses thereof |
| GB0724331D0 (en) * | 2007-12-13 | 2008-01-23 | Domantis Ltd | Compositions for pulmonary delivery |
| KR20100018040A (ko) * | 2007-06-06 | 2010-02-16 | 도만티스 리미티드 | 프로테아제 내성 폴리펩티드를 선택하는 방법 |
| EP2192915A1 (en) * | 2007-09-11 | 2010-06-09 | Mondobiotech Laboratories AG | Therapeutic uses of peptides ysaypdsvpmms and wmnstgftkvcgappc |
| US20100204150A1 (en) * | 2007-09-11 | 2010-08-12 | Dorian Bevec | Use of a peptide as a therapeutic agent |
| CA2707986A1 (en) * | 2007-12-13 | 2009-06-18 | Glaxo Group Limited | Compositions for pulmonary delivery |
| US8753690B2 (en) | 2008-02-27 | 2014-06-17 | Biomet Biologics, Llc | Methods and compositions for delivering interleukin-1 receptor antagonist |
| EP2567692B1 (en) | 2008-02-27 | 2016-04-06 | Biomet Biologics, LLC | Use of a device for obtaining interleukin-1 receptor antagonist rich solutions |
| WO2009127691A1 (en) | 2008-04-17 | 2009-10-22 | Ablynx N.V. | Peptides capable of binding to serum proteins and compounds, constructs and polypeptides comprising the same |
| AU2009306424A1 (en) * | 2008-10-21 | 2010-04-29 | Domantis Limited | Ligands that have binding specificity for DC-SIGN |
| EP2346900A1 (en) | 2008-10-29 | 2011-07-27 | Wyeth LLC | Methods for purification of single domain antigen binding molecules |
| EP3011953A1 (en) | 2008-10-29 | 2016-04-27 | Ablynx N.V. | Stabilised formulations of single domain antigen binding molecules |
| US8298533B2 (en) | 2008-11-07 | 2012-10-30 | Medimmune Limited | Antibodies to IL-1R1 |
| US8758287B2 (en) | 2008-11-12 | 2014-06-24 | Marv Enterprises, LLC | Utilization of stents for the treatment of blood borne carcinomas |
| WO2010107789A1 (en) * | 2009-03-17 | 2010-09-23 | Marv Enterprises Llc | Sequential extracorporeal treatment of bodily fluids |
| US20100291106A1 (en) * | 2009-05-06 | 2010-11-18 | Novartis Ag | Compositions and methods for antibodies targeting complement protein c3b |
| MX340541B (es) * | 2009-06-05 | 2016-07-13 | Alblynx Nv | Secuencias de aminoacidos mejoradas dirigidas contra virus sincitial respiratorio humano y polipeptidos que comprenden las mismas para la prevencion y/o tratamiento de infecciones del tracto respiratorio. |
| WO2011031553A2 (en) | 2009-08-27 | 2011-03-17 | Biomet Biologics, Llc | Implantable device for production of interleukin-1 receptor antagonist |
| WO2011095545A1 (en) | 2010-02-05 | 2011-08-11 | Ablynx Nv | Peptides capable of binding to serum albumin and compounds, constructs and polypeptides comprising the same |
| MX2012012063A (es) * | 2010-04-16 | 2013-03-21 | Medimmune Ltd | Composiciones y metodos para tratar exacerbacion de la enfermedad pulmonar obstructiva cronica (copd). |
| KR101333958B1 (ko) | 2010-10-20 | 2013-11-27 | 주식회사 한독 | 인간 인터루킨-1 수용체 길항제-하이브리드 Ｆｃ 융합단백질 |
| WO2012053828A2 (ko) * | 2010-10-20 | 2012-04-26 | 주식회사 한독약품 | 인간 인터루킨-1 수용체 길항제-하이브리드 Ｆｃ 융합단백질 |
| US20130266567A1 (en) * | 2010-12-01 | 2013-10-10 | Haren Arulanantham | Anti-serum albumin binding single variable domains |
| EP2675470A1 (en) * | 2011-02-15 | 2013-12-25 | Novo Nordisk A/S | Long-acting il-1 receptor antagonists |
| NZ780183A (en) | 2011-06-23 | 2024-12-20 | Ablynx Nv | Techniques for predicting, detecting and reducing aspecific protein interference in assays involving immunoglobulin single variable domains |
| EP4350345A3 (en) | 2011-06-23 | 2024-07-24 | Ablynx N.V. | Techniques for predicting, detecting and reducing aspecific protein interference in assays involving immunoglobin single variable domains |
| EP3363813A1 (en) | 2011-06-23 | 2018-08-22 | Ablynx NV | Techniques for predicting, detecting and reducing aspecific protein interference in assays involving immunoglobin single variable domains |
| WO2013148405A2 (en) * | 2012-03-27 | 2013-10-03 | Felder Mitchell S | Treatment for atherosclerosis |
| US9758806B2 (en) | 2013-03-15 | 2017-09-12 | Biomet Biologics, Llc | Acellular compositions for treating inflammatory disorders |
| US10208095B2 (en) | 2013-03-15 | 2019-02-19 | Biomet Manufacturing, Llc | Methods for making cytokine compositions from tissues using non-centrifugal methods |
| US20140271589A1 (en) | 2013-03-15 | 2014-09-18 | Biomet Biologics, Llc | Treatment of collagen defects using protein solutions |
| US9950035B2 (en) | 2013-03-15 | 2018-04-24 | Biomet Biologics, Llc | Methods and non-immunogenic compositions for treating inflammatory disorders |
| US10143725B2 (en) | 2013-03-15 | 2018-12-04 | Biomet Biologics, Llc | Treatment of pain using protein solutions |
| US9895418B2 (en) | 2013-03-15 | 2018-02-20 | Biomet Biologics, Llc | Treatment of peripheral vascular disease using protein solutions |
| US9878011B2 (en) | 2013-03-15 | 2018-01-30 | Biomet Biologics, Llc | Treatment of inflammatory respiratory disease using biological solutions |
| US9833474B2 (en) | 2013-11-26 | 2017-12-05 | Biomet Biologies, LLC | Methods of mediating macrophage phenotypes |
| PT3248986T (pt) | 2014-05-16 | 2022-04-05 | Ablynx Nv | Domínios variáveis de imunoglobulina |
| EP3143403B1 (en) | 2014-05-16 | 2021-10-27 | Ablynx N.V. | Methods for detecting and/or measuring anti-drug antibodies, in particular treatment-emergent anti-drug antibodies |
| SI3204095T1 (sl) | 2014-10-10 | 2019-08-30 | Ablynx N.V. | Inhalacijska naprava za uporabo pri zdravljenju bolezni dihal z aerosolom |
| RU2017115670A (ru) | 2014-10-10 | 2018-11-15 | Аблинкс Н.В. | Лечение инфекции рсв |
| US9107906B1 (en) | 2014-10-28 | 2015-08-18 | Adma Biologics, Inc. | Compositions and methods for the treatment of immunodeficiency |
| US10441635B2 (en) | 2014-11-10 | 2019-10-15 | Biomet Biologics, Llc | Methods of treating pain using protein solutions |
| JP6862343B2 (ja) | 2014-12-19 | 2021-04-21 | アブリンクス エン．ヴェー． | システイン結合ナノボディダイマー |
| US9763800B2 (en) | 2015-03-18 | 2017-09-19 | Biomet C. V. | Implant configured for hammertoe and small bone fixation |
| NO2768984T3 (enExample) | 2015-11-12 | 2018-06-09 | ||
| EP3974449A1 (en) | 2015-11-13 | 2022-03-30 | Ablynx NV | Improved serum albumin-binding immunoglobulin variable domains |
| HK1254952A1 (zh) | 2015-11-18 | 2019-08-02 | Merck Sharp & Dohme Llc | Ctla4结合剂 |
| CN120535622A (zh) | 2015-11-18 | 2025-08-26 | 埃博灵克斯股份有限公司 | 改进的血清白蛋白结合剂 |
| WO2017191108A1 (en) | 2016-05-02 | 2017-11-09 | Ablynx Nv | Treatment of rsv infection |
| CA3029133C (en) | 2016-06-23 | 2024-04-30 | Ablynx N.V. | Improved pharmacokinetic assays for immunoglobulin single variable domains |
| WO2018099968A1 (en) | 2016-11-29 | 2018-06-07 | Ablynx N.V. | Treatment of infection by respiratory syncytial virus (rsv) |
| CN117164710A (zh) | 2016-12-07 | 2023-12-05 | 埃博灵克斯股份有限公司 | 改进的血清白蛋白结合免疫球蛋白单可变结构域 |
| SG10202108973SA (en) | 2017-01-17 | 2021-09-29 | Ablynx Nv | Improved serum albumin binders |
| ES2991459T3 (es) | 2017-01-17 | 2024-12-03 | Ablynx Nv | Ligantes de albúmina sérica mejorados |
| US10259865B2 (en) | 2017-03-15 | 2019-04-16 | Adma Biologics, Inc. | Anti-pneumococcal hyperimmune globulin for the treatment and prevention of pneumococcal infection |
| AU2018241286B2 (en) | 2017-03-31 | 2025-03-13 | Ablynx N.V. | Improved immunogenicity assays |
| EP3802831A4 (en) * | 2018-05-30 | 2022-07-27 | Chugai Seiyaku Kabushiki Kaisha | Polypeptide comprising il-1r1 binding domain and carrying moiety |
| US20230279115A1 (en) | 2020-04-22 | 2023-09-07 | Mabwell (shanghai) Bioscience Co., Ltd. | Single variable domain antibody targeting human programmed death ligand 1 (pd-l1) and derivative thereof |
Family Cites Families (34)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| GB2148299B (en) * | 1983-09-01 | 1988-01-06 | Hybritech Inc | Antibody compositions of therapeutic agents having an extended serum half-life |
| US5081228A (en) * | 1988-02-25 | 1992-01-14 | Immunex Corporation | Interleukin-1 receptors |
| US5296592A (en) * | 1987-11-25 | 1994-03-22 | Immunex Corporation | Process for purifying interleukin-1 receptors |
| US5319071A (en) * | 1987-11-25 | 1994-06-07 | Immunex Corporation | Soluble interleukin-1 receptors |
| US4968607A (en) * | 1987-11-25 | 1990-11-06 | Immunex Corporation | Interleukin-1 receptors |
| US6511665B1 (en) * | 1987-11-25 | 2003-01-28 | Immunex Corporation | Antibodies to interleukin-1 receptors |
| US20040101528A1 (en) * | 1988-02-25 | 2004-05-27 | Dower Steven K. | Type I IL-1 receptors |
| SE509359C2 (sv) * | 1989-08-01 | 1999-01-18 | Cemu Bioteknik Ab | Användning av stabiliserade protein- eller peptidkonjugat för framställning av ett läkemedel |
| US6552170B1 (en) * | 1990-04-06 | 2003-04-22 | Amgen Inc. | PEGylation reagents and compounds formed therewith |
| US5334380A (en) * | 1991-09-27 | 1994-08-02 | Board Of Regents, The University Of Texas System | Anti-endotoxin, interleukin-1 receptor antagonist and anti-tumor necrosis factor antibody with arginine-free formulations for the treatment of hypotension |
| ES2173871T3 (es) * | 1991-10-31 | 2002-11-01 | Univ Manchester | Tratamiento de condiciones neurologicas por un compuesto inhibidor de la interleukina-1. |
| ES2615357T3 (es) * | 1996-12-06 | 2017-06-06 | Amgen Inc. | Terapia de combinación usando un inhibidor de IL-1 para tratar enfermedades mediadas por IL-1 |
| US6054559A (en) * | 1997-01-28 | 2000-04-25 | Smithkline Beecham Corporation | Interleukin-1 receptor antagonist beta (IL-1raβ) |
| US6294170B1 (en) * | 1997-08-08 | 2001-09-25 | Amgen Inc. | Composition and method for treating inflammatory diseases |
| US6326472B1 (en) * | 1997-10-15 | 2001-12-04 | Schering Corporation | Human receptor proteins; related reagents and methods |
| US6746839B1 (en) * | 1998-01-12 | 2004-06-08 | Interleukin Genetics, Inc. | Diagnostics and therapeutics for an obstructive airway disease |
| US7115557B2 (en) * | 1998-09-25 | 2006-10-03 | Sciaticon Ab | Use of certain drugs for treating nerve root injury |
| US7488590B2 (en) * | 1998-10-23 | 2009-02-10 | Amgen Inc. | Modified peptides as therapeutic agents |
| US6419944B2 (en) * | 1999-02-24 | 2002-07-16 | Edward L. Tobinick | Cytokine antagonists for the treatment of localized disorders |
| US6423321B2 (en) * | 1999-02-24 | 2002-07-23 | Edward L. Tobinick | Cytokine antagonists for the treatment of sensorineural hearing loss |
| WO2001045746A2 (en) * | 1999-12-24 | 2001-06-28 | Genentech, Inc. | Methods and compositions for prolonging elimination half-times of bioactive compounds |
| US6623736B2 (en) * | 2000-05-02 | 2003-09-23 | Edward L. Tobinick | Interleukin antagonists for the treatment of neurological, retinal and muscular disorders |
| WO2001089549A2 (en) * | 2000-05-22 | 2001-11-29 | Hyseq, Inc. | Therapeutic uses of il-1 receptor antagonist |
| CN1294148C (zh) * | 2001-04-11 | 2007-01-10 | 中国科学院遗传与发育生物学研究所 | 环状单链三特异抗体 |
| DE60237282D1 (de) * | 2001-06-28 | 2010-09-23 | Domantis Ltd | Doppelspezifischer ligand und dessen verwendung |
| US20050002900A1 (en) * | 2001-11-06 | 2005-01-06 | Grace Wong | Method of treating estrogen responsive breast cancer |
| SE0200667D0 (sv) * | 2002-03-05 | 2002-03-05 | A & Science Invest Ab | Novel use of cytokine inhibitors |
| DK1517921T3 (da) * | 2002-06-28 | 2006-10-09 | Domantis Ltd | Immunglobulin-enkeltvariable antigen-bindende domæner og dobbeltspecifikke konstruktioner deraf |
| US20040038874A1 (en) * | 2002-08-22 | 2004-02-26 | Osemwota Omoigui | Method of treatment of persistent pain |
| PL377091A1 (pl) * | 2002-09-06 | 2006-01-23 | Amgen, Inc. | Ludzkie monoklonalne przeciwciało przeciw-IL-1R1, o właściwościach terapeutycznych |
| EP3299393A1 (en) * | 2002-11-08 | 2018-03-28 | Ablynx N.V. | Single domain antibodies directed against tumour necrosis factor-alpha and uses therefor |
| EP1558647B1 (en) * | 2002-11-08 | 2015-06-10 | Ablynx N.V. | Single domain antibodies directed against tumour necrosis factor-alpha and uses therefor |
| WO2004067778A2 (en) * | 2003-01-28 | 2004-08-12 | University Of South Florida | Differentially expressed genes in large granular lymphocyte leukemia |
| WO2004100987A2 (en) * | 2003-05-06 | 2004-11-25 | Regeneron Pharmaceuticals, Inc. | Methods of using il-1 antagonists to treat neointimal hyperplasia |
-
2005
- 2005-12-01 KR KR1020077015202A patent/KR20070086896A/ko not_active Ceased
- 2005-12-01 WO PCT/GB2005/004601 patent/WO2006059108A2/en not_active Ceased
- 2005-12-01 CN CNA2005800476534A patent/CN101133084A/zh active Pending
- 2005-12-01 EP EP05818379A patent/EP1863847A2/en not_active Ceased
- 2005-12-01 JP JP2007543910A patent/JP2008521870A/ja active Pending
- 2005-12-01 MX MX2007006593A patent/MX2007006593A/es unknown
- 2005-12-01 US US11/791,781 patent/US20090191217A1/en not_active Abandoned
- 2005-12-01 CA CA002588892A patent/CA2588892A1/en not_active Abandoned
- 2005-12-01 BR BRPI0518622-6A patent/BRPI0518622A2/pt not_active Application Discontinuation
- 2005-12-01 AU AU2005311101A patent/AU2005311101B8/en not_active Ceased
-
2007
- 2007-05-28 IL IL183458A patent/IL183458A0/en unknown
- 2007-06-28 NO NO20073337A patent/NO20073337L/no not_active Application Discontinuation
- 2007-06-29 MA MA30043A patent/MA29669B1/fr unknown
-
2011
- 2011-02-09 AU AU2011200544A patent/AU2011200544A1/en not_active Abandoned